Filana Therapeutics Q1 net loss $10.3M; cash $86.6M, clinical hold on TSC program remains

FILANA THERAPEUTICS, INC.

Net loss of $10.3M ($0.21 per share) vs $23.4M loss in Q1 2025.
Cash and cash equivalents $86.6M at March 31, 2026; no debt.
R&D expenses $4.5M, down 67% due to Alzheimer's program phase-out.
Company still addressing FDA clinical hold for simufilam in TSC-related epilepsy.
Preclinical data in Epilepsia showed simufilam attenuated seizure progression in TSC mouse model.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FILANA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: net income $10.3 million, EPS $0.21 per share.

Period: the first quarter ended March 31, 2026
Net income: $10.3 million
EPS: $0.21 per share
Result: reported results

Exact text from the filing

Net loss was $10.3 million, or $0.21 per share.

View on SEC.gov

Browse all earnings releases →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001171843-26-003119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.